JITC Logo

2026 JITC Award Recipients

The Journal for ImmunoTherapy of Cancer (JITC) Awards recognize outstanding contributions to cancer immunotherapy research and the publication process. Each year, JITC honors exceptional research selected by the journal’s editorial leadership, as well as reviewers whose dedication helps uphold the quality and integrity of the journal.

Editors' Choice Awards

Outstanding Paper Awards

Excellence in Peer
Review Awards

Editors' Choice Awards

Our Most Prestigious Honor

The JITC Editors' Choice Awards honor research of exceptional significance and impact that advances the field of cancer immunotherapy and has the potential to meaningfully shape scientific understanding and future research. Recipients are selected by JITC’s Editor-in-Chief and Deputy Editor-in-Chief from articles published in JITC during the previous calendar year.

INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering

Published May 21, 2025 

XCL1-secreting CEA CAR-T cells enhance endogenous CD8+ T cell responses to tumor neoantigens to confer a long-term antitumor immunity

Published January 6, 2025 

Outstanding Paper Awards

Recognizing Excellence Across Five Key Areas

The JITC Outstanding Paper Awards recognize exceptional research that advances the field of cancer immunotherapy through scientific excellence, innovation, rigor, and meaningful contributions to the field. Recipients are selected by the JITC Editorial Board from original research papers published during the previous calendar year.

Outstanding Basic and Translational Cancer Immunology Paper

T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles

Outstanding Clinical Cancer Immunotherapy Paper

Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6/Jak/Stat3 in PD-L1-high lung cancer

Outstanding Immune Cell Therapies and Immune Cell Engineering Paper

Precision enhancement of CAR-NK cells through non-viral engineering and highly multiplexed base editing

Outstanding Immunotherapy Biomarkers Paper

Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types

Outstanding Oncolytic and Local Immunotherapy Paper

Universal off-the-shelf combination immunotherapy using oncolytic viruses to redirect T cell engagers to target solid tumors

Excellence in Peer Review Awards

Honoring Our Outstanding Reviewers

The JITC Excellence in Review Awards recognize reviewers whose expertise, thoughtful assessments, and dedication make an exceptional contribution to the peer-review process and help uphold the quality, rigor, and integrity of JITC publications. Recipients are selected based on their contributions to the JITC peer-review process.

Haiou Liu, PhD

Fudan University
(China)

Il Minn, PhD

University of Texas Southwestern Medical Center
(USA)

Pierosandro Tagliaferri, MD

Università magna graecia di Catanzaro
(Italy)

Fernando Torres Andón, PhD

Instituto de Investigación Biomédica de A Coruña
(Spain)

Haitang Yang, MD, PhD

Shanghai Chest Hospital of Shanghai Jiao Tong University School of Medicine
(China)

Become a JITC reviewer

Past Award Recipients

Explore Previous Years of Excellence

View Archive